Pfizer Articles
US FDA panel backs Novartis’ Afinitor and Pfizer’ Sutent for rare cancer, and agency OKs Merck & Co’s Sylatron for melanoma
13 April 2011
European Commission clears Pfizer’s Dupuytren’s drug Xiapex and added use for Bristol-Myers’ Baraclude
2 March 2011
US FDA stalls Protalix Gaucher drug taliglucerase, calling for more data, but not new trials
28 February 2011
India’s Aurobindo to lose $2 million a month due to US FDA ban alert
25 February 2011
US Supreme Court decides for vaccine makers in Pfizer/Wyeth case
24 February 2011
PDL BioPharma to pay MedImmune $92.5 million to resolve patent disputes; Mylan debuts generic Vfend
17 February 2011
As GSK and Pfizer roll out pneumococcal vaccines in Kenya, MSF asks are donors getting a fair deal?
11 February 2011
Diabetes pipeline cannot reverse cardiovascular and metabolic market decline, says Datamonitor
10 February 2011
Pfizer’s 4th-quarter 2010 results beat expectations but guidance disappoints; $5 billion share buyback
2 February 2011
Melanoma drug market to see CAGR of 16.8% to reach $1.42 billion by 2017; pneumo- and meningococcal vaccines forecast
31 January 2011
USA and China plan increasing private-public collaboration in the health care sector
25 January 2011
Global glaucoma therapeutics market was worth $3.9 billion in 2009 but will see generic erosion
20 January 2011
Final appraisal from UK’s NICE backs improved treatment access for early Alzheimer’s disease; SMC negative for Nexavar
18 January 2011
Pfizer commences rolling FDA submission for lung cancer drug crizotinib; denies German VAT evasion
17 January 2011
Pfizer acquires rights to develop Sutro Biopharma’s novel peptide-based therapeutics
10 January 2011
USA’s FDA puts stops on Johnson & Johnson’s fulranumab and Regeneron/Sanofi-Aventis osteo drug due to side effect risks
4 January 2011
Transition Thera modifies Alzheimer’s drug deal with Elan; King re-submits Remoxy NDA
4 January 2011
As patent cliffs and law suits rule US generic drug industry, research-based majors look to deals and diversification
4 January 2011
Pfizer signs up to $511 million deal for Lpath’s AMD treatment and $134 million accord for Phylogica’s for peptide-based vaccines
21 December 2010
Public Citizen says Pharma is biggest defrauder of US federal government under False Claims Act
20 December 2010
EMA advised Pfizer is withdrawing Thelin due to serious liver damage; starts somatropin drugs review
13 December 2010
Aromatase inhibitors may increase risk of heart disease in postmenopausal women with breast cancer
10 December 2010
Australia’s fight against cancer continues with new additions to the PBS, says health minister
10 December 2010
ASH meeting: Pfizer’s bosutinib disappoints in myeloid leukemia trial; Novartis’ Tasigna beats Glivec in CML study
7 December 2010
Read succeeds Pfizer president and CEO Kindler, who has suddenly retired from the company; announces compliance fund
6 December 2010
Europe clears new indication for Pfizer’s Sutent; first approval for Sumavel DosePro in Denmark
3 December 2010
US Justice Dept recovers $3 billion in false claims cases in FY 2010, with record $2.5 billion in health care fraud
23 November 2010
Pfizer extends $3.6 billion tender offer for King Pharma, as all conditions still not met
23 November 2010
Bristol-Myers Squibb and Pfizer drop development of apixaban in acute coronary syndrome, but good news for Pfizer with axitinib
22 November 2010
Pfizer links with academia in Global Centers for Therapeutic Innovation, starting with up to $85 million accord with UCSF
17 November 2010
Heart meeting hears disappointing results for J&J/Scios Natrecor; strong findings for Pfizer’s Inspra
15 November 2010
Can Pfizer rescue hormonal replacement therapy with its Aprela?
9 November 2010
Pfizer’s tasocitinib reduced signs and symptoms of rheumatoid arthritis in Ph III study; New data on Roche’s Actemra in RA
8 November 2010
Pfizer/Ligand’s lasofoxifene reduces breast cancer risk in postmenopausal osteoporotic women
8 November 2010
New compounds may treat both alcohol and cigarette addictions
5 November 2010
Novartis’ Onbrez Breezhaler beats Spiriva in new study of COPD patients; Afinitor reduces SEGAs size
4 November 2010
Pfizer’s 3rd-qtr 2010 net income slumps 70%, but adjusted for charges still beat forecasts
3 November 2010
New Zealand’s PHARMAC seals deal with Pfizer for new kidney cancer, smoking cessation and arthritis drugs
1 November 2010
Negative decisions from UK’s NICE for Novartis’ Xolair, GSK’s Arzerra and Pfizer’s Torisel, but OK for Amgen’s Prolia
27 October 2010
Despite economic crisis, top EU firms cut R&D investment less than US rivals, but Europe still behind; strong pharma showing
27 October 2010
Commission clears JV by DocMorris and K-Mail Order; OK’s Pfizer’s pediatric Xalatan and Meda’s Breakyl
22 October 2010
Another foray into generics by Pfizer as it buys 40% stake in Brazil’s Teuto for $240 million upfront
21 October 2010
Outlook for generic equivalent of Pfizer’s Lipitor; how will US exclusivity resolve? asks law firm HPM
14 October 2010
Pfizer rolls out osteoporosis drug bazedoxifene in Japan
14 October 2010
Pfizer on the acquisition trail again, snapping up King Pharmaceuticals for $3.6 billion
13 October 2010
Pfizer views options for Capsugel business, including selling the unit; closed FoldRx acquisiton
7 October 2010
New report reveals inefficient management of chronic pain costs Europe billions of euros each year
6 October 2010
Pfizer calls a halt to Phase III study of Sutent in prostate cancer
28 September 2010
Spiriva a possible alternative therapy for adults with poorly controlled asthma; Daxas reduces harmful lung attacks, ERS conference hears
21 September 2010
Alzheimer's drug market to more than triple to $13.3 billion in 2019 in top seven markets, fuelled by new biologic agents
10 September 2010
Pfizer returns worldwide rights to Celldex Thera’s rindopepimut brain tumor vaccine candidate
6 September 2010
Pfizer to buy privately-held drug discovery firm FoldRx to expand rare diseases portfolio
2 September 2010
Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
2 September 2010
Two blockbuster potential stroke/DVT drugs report good results at ESC Congress: Bristol-Myers/Pfizer’s apixaban and Bayer/J&J’s rivaroxaban
1 September 2010
Pfizer’s Sutent fails to meet endpoint in NSCLC study; Prevenar 13 gains WHO pre-qualification
25 August 2010
Charles River calls off WuXi Pharmatech buy on shareholder opposition; Pfizer sells Idun to Conatus
2 August 2010
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
